Autoimmune presentations are rarely explained by a single gene or pathway. When VDR optimization and foundational methylation support have been addressed and patients are still struggling, the next layer of the genetic picture typically involves HLA variants, methylation-dependent T cell regulation, and the nitric oxide pathway. Understanding these mechanisms — and how they interact — is what separates a partial clinical response from a more complete one.
This post is Part 2 of our clinical series on immune genetics. Read Part 1 on VDR and T cell activation here. It’s written for licensed and certified practitioners working with the MyHappyGenes® reports.
TH1/TH2/TH17 Balance: The Clinical Framework
Before addressing specific genes, it’s worth grounding the discussion in the T helper cell balance framework that underlies most autoimmune presentations.
TH1 cells drive cellular immunity — directing cytotoxic T cells and macrophages to eliminate intracellular pathogens. TH1 dominance is associated with inflammatory autoimmune conditions including rheumatoid arthritis, multiple sclerosis, and type 1 diabetes.
TH2 cells drive humoral immunity — stimulating B cell antibody production. TH2 dominance is associated with allergic conditions, asthma, and atopic presentations.
TH17 cells are a proinflammatory subset particularly associated with mucosal immunity and tissue-directed autoimmunity. TH17 dominance is strongly linked to Hashimoto’s thyroiditis, psoriasis, and inflammatory bowel disease.
T regulatory cells (Tregs) suppress excessive immune activation and are the critical brake on autoimmune disease development. Treg dysfunction is a central mechanism in most autoimmune conditions — and as covered in Part 1, Treg function is heavily regulated by VDR.
For practitioners using Wholistic Methylation muscle testing, hypersensitivity responses to TH1 and TH2 challenge vials indicate overstimulation of the respective pathway — a useful clinical screen for identifying immune dominance patterns before building a protocol.
HLA Variants: The Self/Non-Self Recognition System
The HLA system — Human Leukocyte Antigens, corresponding to the Major Histocompatibility Complex — enables the immune system to distinguish self from non-self by presenting antigens to T cells. Variants in HLA genes are among the strongest known genetic risk factors for autoimmune disease and deserve focused clinical attention when they appear on the MyHappyGenes® report.
MHC Class I variants (HLA-A, HLA-B, HLA-C) present intracellular peptides to cytotoxic T cells. Clinically significant variants include HLA-B27, associated with ankylosing spondylitis and seronegative spondyloarthropathies, and HLA-B8, associated with Graves disease, Addison’s disease, and myasthenia gravis.
MHC Class II variants (HLA-DR, HLA-DQ, HLA-DP) present extracellular antigens to helper T cells, driving antibody production. These carry the strongest autoimmune associations on the report:
HLA-DRB1 variants are associated with type 1 diabetes, rheumatoid arthritis, multiple sclerosis, lupus, ankylosing spondylitis, and celiac disease. [1]
HLA-DQA1 and HLA-DQB1 variants carry strong celiac disease associations. Patients with these variants should receive clear and direct guidance around gluten elimination — the genetic susceptibility here is significant enough that even subclinical gluten exposure warrants serious clinical attention.
When three or more HLA variants appear on a patient’s report, the clinical picture typically warrants extra caution and proactive intervention — these patients have a higher baseline autoimmune risk and are less forgiving of protocol gaps.
Molecular Mimicry: How HLA Variants Trigger Autoimmunity
Molecular mimicry is one of the most important mechanisms through which HLA variants contribute to autoimmune disease onset — and one of the least discussed in functional medicine contexts.
When the MHC molecule presents both a pathogen peptide and a structurally similar self-peptide to T cells, the activated immune response can mistake host tissue for the pathogen. The T cell learns to attack what it should be protecting.
Rheumatic fever following group A streptococcal infection is the classic textbook example — streptococcal M proteins resemble cardiac tissue proteins closely enough that antibodies produced against the infection attack heart valves. But the same mechanism is implicated in thyroid autoimmunity following viral infection, in neurological autoimmune conditions, and in joint-directed autoimmunity following gut infections.
Clinically this is why a thorough infection history matters in autoimmune cases. A patient whose Hashimoto’s began shortly after a significant viral illness, or whose rheumatoid arthritis followed a bacterial infection, may have molecular mimicry as a contributing initiating mechanism — one that HLA variants made them genetically susceptible to.
Methylation and T Cell Proliferation
Proper methylation is foundational to T cell function in ways that extend well beyond the neurotransmitter and detoxification roles most practitioners focus on.
T cells require rapid DNA synthesis to proliferate during an immune response — and methylation provides the nucleotide building blocks for that synthesis. When methylation is impaired, T cell proliferation is impaired along with it. Fewer T cells, particularly T regulatory cells, means a weaker and less regulated immune response.
The evidence in autoimmune disease is clear: research in lupus patients has consistently demonstrated that their T cells are undermethylated — and that as methylation function recovers, immune regulation tends to recover alongside it. [2] This makes methylation support a foundational autoimmune intervention, not just a mood and neurological one.
A second methylation-immune mechanism involves SAMe — the body’s primary methyl donor. When SAMe is depleted (as occurs with CBS upregulation, MTHFR impairment, or both), T cell methylation patterns become abnormal. Autoreactive T cell behavior has been directly linked to SAMe depletion in animal models of lupus. [3]
Key methylation variants to assess in complex autoimmune cases alongside HLA findings:
MTHFR variants impairing active folate availability for DNA synthesis. MTR/MTRR variants affecting B12-dependent remethylation. CBS variants depleting SAMe and impairing downstream methylation broadly. Glutathione variants reducing antioxidant capacity and increasing oxidative stress on immune cells.
NOS2 and Innate Immune Defense
NOS2 — inducible nitric oxide synthase — is the immune system’s primary direct pathogen-killing mechanism and one of the most clinically underappreciated genes in functional immune genetics.
When macrophages detect a pathogen, NOS2 generates nitric oxide which converts to peroxynitrite and superoxide — reactive oxygen species that are directly cytotoxic to viruses, bacteria, parasites, and fungi. [4] This is a foundational innate immune defense mechanism that operates independently of the adaptive immune response — it’s the body’s first strike capability.
NOS2 variants impair this killing capacity. Patients with NOS2 variants are more susceptible to infection and slower to clear pathogens once infected. They may also show impaired tumor surveillance, since NOS2-generated reactive oxygen species participate in identifying and destroying abnormal cells.
Vitamin D is a key cofactor for NOS2 activation — creating an important clinical link between VDR function covered in Part 1 and NOS2 activity here. In patients with both VDR and NOS2 variants, innate immune defense is impaired at two levels simultaneously: the activation signal is weak and the killing mechanism is also compromised.
The downstream reactive oxygen species generated by NOS2 must be efficiently cleared to prevent oxidative damage to healthy tissue. SOD (superoxide dismutase) and catalase are the primary enzymes responsible for this clearance — and variants in these genes can allow oxidative stress to accumulate even when NOS2 function is adequate. Glutathione and ergothioneine provide additional antioxidant support for this pathway and are worth assessing in patients with both NOS2 and SOD/catalase variants.
Interleukin Variants
The MyHappyGenes® report currently includes three interleukin variants with well-established clinical evidence:
IL-1 variants impair lymphocyte activation, macrophage stimulation, and fever response — reducing the body’s ability to mount an effective initial defense against infection.
IL-2 variants affect T cell proliferation and differentiation, including Treg development — with significant implications for autoimmune susceptibility.
IL-12 variants impair TH1 cell induction and natural killer cell activation — reducing cellular immune competence against intracellular pathogens.
Additional interleukin variants will be added to the report as the supporting evidence base matures.
Cofactor and Supplement Protocol
Specific dosing should always be determined by the practitioner based on the patient’s full variant picture, current health status, medication interactions, and clinical response.
HLA variant support: PEA (palmitoylethanolamide) has shown clinical utility for modulating HLA variant activity and is worth considering in patients with multiple HLA variants. SPMs (specialized pro-resolving mediators) support resolution of chronic inflammation and are a useful adjunct in autoimmune presentations. Methylation support via activated B12 and methylfolate addresses the methylation component of HLA-related immune dysregulation.
Methylation support: Active folate (5-MTHF) and methylcobalamin foundationally, with riboflavin, magnesium, and zinc as cofactors. TMG as an alternative remethylation pathway where methylfolate sensitivity is present. Start conservatively in patients with concurrent low COMT or MAO-A variants.
NOS2 support: Nitric oxide precursor support alongside antioxidant support for downstream reactive oxygen species clearance — SOD, catalase, glutathione precursors, and ergothioneine. VDR optimization (covered in Part 1) is a necessary prerequisite for adequate NOS2 activation.
Essential fatty acids: Omega-3 fatty acids support membrane function and modulate inflammatory signaling broadly — a foundational intervention in most autoimmune and chronic inflammatory presentations.
Kinesiology Challenge Vials
For practitioners using applied kinesiology alongside the MyHappyGenes® report, relevant challenge vials for this section include: TH1, TH2, TH17, Tregs, HLA panel (full), Interleukins (all), Nitric Oxide, Superoxide, Peroxynitrite, SOD, Catalase, Glutathione, SAMe, Methyl Donors, and the organ sweep kit for identifying tissues under autoimmune attack.
Clinical Sequencing in Complex Autoimmune Cases
When multiple immune-related variants are present across both posts in this series, clinical sequencing matters. A general framework based on pathway interdependencies:
Start with methylation — T cell proliferation depends on it and it underpins almost everything else. Address VDR next — T cell activation and Treg function both depend on it, and it has the broadest downstream impact. Support NOS2 alongside VDR — both require vitamin D and their effects on innate immunity are complementary. Address HLA-specific support — PEA and SPMs — once foundational pathways are stabilized. Monitor and adjust based on clinical response throughout.
This is a framework, not a rigid protocol. Individual variant combinations, patient tolerance, and clinical presentation will always guide actual sequencing decisions.
Key Variant Interactions
HLA + VDR: HLA variants increase autoimmune susceptibility while VDR variants reduce Treg activity — the critical brake on autoimmune overactivation. This combination warrants particular clinical attention and proactive VDR optimization before addressing HLA directly.
HLA + MTHFR: Undermethylated T cells in MTHFR patients are more prone to autoreactive behavior in the context of HLA variants — compounding autoimmune risk through two distinct mechanisms. Methylation support is foundational before HLA-targeted interventions.
NOS2 + SOD/Catalase: When NOS2 generates reactive oxygen species that SOD and catalase can’t efficiently clear, oxidative damage accumulates alongside pathogen killing. Antioxidant support is as important as NOS2 activation in these patients — the two go together.
NOS2 + VDR: Covered in Part 1 — VDR activation is required for adequate NOS2 expression. These two should always be assessed and addressed together in patients with innate immune compromise.
MTHFR + HLA: Methylation impairment and HLA susceptibility together represent one of the most common combinations in complex autoimmune presentations. Addressing MTHFR first consistently produces better downstream outcomes when both are present.
References
-
- Klimi E. “HLA DRB1* Allele Lupus Erythematosus, Rheumatoid Arthritis, and other Autoimmune Disorders.” Mediterranean Journal of Rheumatology, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12183449/
-
- Richardson B, et al. “Role of T cell DNA methylation in lupus syndromes.” Lupus, 1994. https://pubmed.ncbi.nlm.nih.gov/7535621/
-
- “Lupus autoimmunity altered by cellular methylation metabolism.” PubMed, 2012. https://www.ncbi.nlm.nih.gov/pubmed/23039363
-
- Bogdan C. “The role of nitric oxide in innate immunity.” PubMed, 2000. https://pubmed.ncbi.nlm.nih.gov/10719664/
Working With MyHappyGenes® Reports
Immune-related variants in this post appear across the Biochemical Pathways Analysis and the Healthy Genes Analysis sections of the MyHappyGenes® report. Because HLA, methylation, and NOS2 pathways interact so significantly with VDR (covered in Part 1), reviewing both posts alongside the full report produces the most complete clinical picture.
If you’re not yet working with MyHappyGenes® reports in your practice, learn more about our practitioner program here.
That gives you two focused, clinically deep posts that work as a natural series. The citations are embedded in both. Ready for post #6 — Histamine and DAO/HNMT — whenever you are.
